Editing Post-exposure prophylaxis (section)

==COVID-19==
In 2021, the US [[FDA]] gave [[emergency use authorization]] (EUA) to [[bamlanivimab/etesevimab]] for post-exposure prophylaxis against [[COVID-19]].<ref>{{cite web |last1=Research |first1=Center for Drug Evaluation and |title=FDA authorizes bamlanivimab and etesevimab monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19 |url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis |website=FDA |language=en |date=16 September 2021 |access-date=24 April 2022 |archive-date=17 September 2021 |archive-url=https://web.archive.org/web/20210917083810/https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-bamlanivimab-and-etesevimab-monoclonal-antibody-therapy-post-exposure-prophylaxis |url-status=dead }}</ref> However, due to its reduced effectiveness against [[SARS-CoV-2 Omicron variant|Omicron variant]]s of the SARS-CoV-2 virus, it is no longer recommended for this purpose.<ref name="NIH 2023">{{cite web |title=Prevention of SARS-CoV-2 |website=NIH |date=20 December 2023 |url=https://www.covid19treatmentguidelines.nih.gov/overview/prevention-of-sars-cov-2/ |access-date=27 January 2024}}</ref>

[[Ensitrelvir]] has been studied for its potential use as post-exposure prophylaxis against COVID-19 in a phase 3 clinical trial.<ref>{{cite web |last=Cosdon |first=Nina |title=Ensitrelvir: A COVID-19 Antiviral That Remains Effective Against New Variants |website=ContagionLive |date=31 March 2023 |url=https://www.contagionlive.com/view/ensitrelvir-a-covid-19-antiviral-that-remains-effective-against-new-variants |access-date=28 October 2023 |archive-date=31 October 2023 |archive-url=https://web.archive.org/web/20231031071100/https://www.contagionlive.com/view/ensitrelvir-a-covid-19-antiviral-that-remains-effective-against-new-variants |url-status=live }}</ref><ref >{{cite web |title=Shionogi presses on with Xocova research following Japanese approval |website=[[The Pharma Letter]] |date=16 February 2023 |url=https://www.thepharmaletter.com/article/shionogi-presses-on-with-xocova-research-following-japanese-approval |access-date=28 October 2023 |archive-date=28 October 2023 |archive-url=https://web.archive.org/web/20231028053044/https://www.thepharmaletter.com/article/shionogi-presses-on-with-xocova-research-following-japanese-approval |url-status=live }}</ref><ref>{{cite web |title=Studies Currently Enrolling |website=University of Kansas Medical Center |url=https://www.kumc.edu/school-of-medicine/campuses/wichita/research/center-for-clinical-research-wichita/clinical-trials/studies-currently-enrolling.html |access-date=28 October 2023 |archive-url=https://web.archive.org/web/20231028051723/https://www.kumc.edu/school-of-medicine/campuses/wichita/research/center-for-clinical-research-wichita/clinical-trials/studies-currently-enrolling.html |archive-date=28 October 2023 |quote=SCORPIO-PEP is a 28-day study to assess the prevention of COVID-19 infection in those who have been exposed through household contact.}}</ref> Top-line results from this trial suggested that use of ensitrelvir as post-exposure prophylaxis may significantly reduce the risk of symptomatic COVID-19 infection in exposed household contacts compared to placebo.<ref name="Ernst 2024">{{cite web |vauthors=Ernst D |title=Ensitrelvir Looks Promising for COVID-19 Postexposure Prophylaxis |website=MPR |date=8 November 2024 |url=https://www.empr.com/news/ensitrelvir-looks-promising-for-covid-19-postexposure-prophylaxis/ |access-date=25 January 2025}}</ref><ref name="ContagionLive 2024">{{cite web |title=Antiviral Prevents Symptomatic COVID-19 in Post-Exposure Prophylactic Study |website=ContagionLive |date=29 October 2024 |url=https://www.contagionlive.com/view/antiviral-prevents-symptomatic-covid-19-in-post-exposure-prophylactic-study |access-date=25 January 2025}}</ref><ref name="Swift 2024">{{cite web |vauthors=Swift R |title=Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission |website=Reuters |date=29 October 2024 |url=https://www.reuters.com/business/healthcare-pharmaceuticals/japans-shionogi-says-phase-3-study-showed-covid-pill-reduces-transmission-2024-10-29/ |access-date=25 January 2025}}</ref>